Physician profile
Michael A Allon
NPI 1649348699
$1,402.85
in general payments reported to CMS, 2019-2025
14 companies · $60.07 in 2025
The $60.07 reported for 2025 was less than what a typical Reproductive Endocrinology provider received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2020: $258 · 2021: $231 · 2022: $315 · 2023: $224 · 2024: $107 · 2025: $60.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $391.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $436.72 | 2019-2023 | Menopur |
| Abbvie INC. | $275.06 | 2019-2023 | Orilissa, Lo Loestrin Fe |
| Organon LLC | $172.75 | 2022-2025 | Pregnyl, Follistim Aq, Ganirelix Acetate |
| Mayne Pharma Commercial LLC | $102.63 | 2021-2023 | |
| Coopersurgical, INC. | $99.25 | 2020 | |
| Caldera Medical, INC | $85.38 | 2023 | Desara |
| Galen US INC | $50.15 | 2021 | |
| Hologic Sales and Service, LLC | $43.33 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $36.16 | 2023 | Myfembree |
| Exeltis, USA INC. | $32.63 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $19.26 | 2022 | |
| Duchesnay USA Incorporated | $17.72 | 2019 | |
| Myovant Sciences INC. | $17.26 | 2022 | |
| Therapeuticsmd, INC. | $14.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Allon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.